Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
Public ClinicalTrials.gov record NCT03212521. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1 - 6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Study identification
- NCT ID
- NCT03212521
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 230 participants
Conditions and interventions
Conditions
Interventions
- Glecaprevir/Pibrentasvir Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 6, 2017
- Primary completion
- Aug 12, 2018
- Completion
- Aug 12, 2018
- Last update posted
- Sep 3, 2019
2017 – 2018
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Parkway Medical Center /ID# 161261 | Birmingham | Alabama | 35215 | — |
| Arkansas Gastroenterology /ID# 161266 | North Little Rock | Arkansas | 72117 | — |
| UC Davis Medical Center /ID# 161138 | Sacramento | California | 95817 | — |
| Yale University /ID# 161258 | New Haven | Connecticut | 06510 | — |
| Univ Maryland School Medicine /ID# 161157 | Baltimore | Maryland | 21201 | — |
| Digestive Disease Associates - Baltimore /ID# 161260 | Baltimore | Maryland | 21229 | — |
| University of Michigan Hospitals /ID# 161265 | Ann Arbor | Michigan | 48109-5008 | — |
| Northwest Gastroenterology Cli /ID# 161257 | Portland | Oregon | 97210 | — |
| Liver Associates of Texas, P.A /ID# 161262 | Houston | Texas | 77030-2783 | — |
| University of Vermont Medical Center /ID# 161263 | Burlington | Vermont | 05401-1473 | — |
| Digestive and Liver Disease Sp /ID# 161259 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03212521, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2019 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03212521 live on ClinicalTrials.gov.